Xarelto (rivaroxaban) / J&J 
Welcome,         Profile    Billing    Logout  
 97 Diseases   247 Trials   247 Trials   14602 News 


«12...152153154155156157158159160161162...170171»
  • ||||||||||  rivaroxaban / Generic mfg.
    Trial completion date, Trial primary completion date:  EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis (clinicaltrials.gov) -  Jul 12, 2018   
    P3,  N=170, Recruiting, 
    Trial completion date: Jul 2019 --> Jan 2019 | Trial primary completion date: Jul 2019 --> Jan 2019
  • ||||||||||  rivaroxaban / Generic mfg., lenalidomide / Generic mfg., aspirin / Generic mfg.
    Trial initiation date, Combination therapy:  RithMM: Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma (clinicaltrials.gov) -  Jun 29, 2018   
    P2/3,  N=86, Not yet recruiting, 
    Rivaroxaban was associated with shortened LOS and lowered cost vs parenterally bridged warfarin in PE observation stay patients, without increases in the short-term rate of complications or readmission. Initiation date: Mar 2018 --> Jul 2018
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Trial primary completion date:  Start or STop Anticoagulants Randomised Trial (SoSTART) (clinicaltrials.gov) -  Jun 28, 2018   
    P3,  N=800, Recruiting, 
    Initiation date: Mar 2018 --> Jul 2018 Trial primary completion date: Jul 2022 --> Jul 2021
  • ||||||||||  rivaroxaban / Generic mfg., aspirin / Generic mfg.
    Trial primary completion date:  Rivaroxaban or Aspirin for Biological Aortic Prosthesis (clinicaltrials.gov) -  Jun 27, 2018   
    P4,  N=1000, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> May 2018 | Trial primary completion date: Dec 2018 --> Oct 2017 Trial primary completion date: Nov 2020 --> Nov 2022
  • ||||||||||  rivaroxaban / Generic mfg.
    Trial completion, Adherence:  Smartphones to Improve Rivaroxaban ADHEREnce in Atrial Fibrillation (clinicaltrials.gov) -  Jun 19, 2018   
    P4,  N=139, Completed, 
    Rivaroxaban significantly reduced hospital LOS and costs compared to parenterally bridged warfarin, without increasing the risk of readmission. Active, not recruiting --> Completed
  • ||||||||||  rivaroxaban / Generic mfg.
    Trial completion date, Trial primary completion date:  The Effect of Rivaroxaban in Sickle Cell Disease (clinicaltrials.gov) -  Jun 18, 2018   
    P2,  N=34, Enrolling by invitation, 
    Active, not recruiting --> Completed Trial completion date: May 2018 --> Dec 2018 | Trial primary completion date: May 2018 --> Dec 2018
  • ||||||||||  rivaroxaban / Generic mfg.
    Clinical Trial,Phase I, Clinical Trial,Phase II, Clinical Trial,Phase III, Journal:  Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. (Pubmed Central) -  Jun 16, 2018   
    P3
    Conclusions Rivaroxaban was not superior to aspirin with regard to the prevention of recurrent stroke after an initial embolic stroke of undetermined source and was associated with a higher risk of bleeding. (Funded by Bayer and Janssen Research and Development; NAVIGATE ESUS ClinicalTrials.gov number, NCT02313909 .).
  • ||||||||||  Journal:  Direct oral anticoagulants in the treatment of pulmonary embolism. (Pubmed Central) -  Jun 15, 2018   
    However, questions remain pertaining to the use of DOACs in PE patients with high-risk features and in cancer patients and fragile populations. Clinical studies are under way to address many of these issues.
  • ||||||||||  rivaroxaban / Generic mfg.
    Trial primary completion date:  EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis (clinicaltrials.gov) -  Jun 14, 2018   
    P3,  N=170, Recruiting, 
    Clinical studies are under way to address many of these issues. Trial primary completion date: Jul 2018 --> Jul 2019
  • ||||||||||  rivaroxaban / Generic mfg.
    Trial completion date, Trial primary completion date:  JPMS-XAR-VTE: Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE) (clinicaltrials.gov) -  Jun 11, 2018   
    P=N/A,  N=1250, Recruiting, 
    Trial completion date: Apr 2020 --> Apr 2021 | Trial primary completion date: Apr 2018 --> Apr 2019 Trial completion date: Jan 2020 --> Mar 2021 | Trial primary completion date: Mar 2019 --> Mar 2020
  • ||||||||||  Xarelto (rivaroxaban) / J&J
    Trial primary completion date, Surgery:  Utilization of TEG to Monitor Rivaroxaban Activity (clinicaltrials.gov) -  Jun 3, 2018   
    P=N/A,  N=100, Recruiting, 
    Recruiting --> Active, not recruiting Trial primary completion date: Mar 2018 --> Aug 2018
  • ||||||||||  Review, Journal:  Adjuncts to Blood Component Therapies for the Treatment of Bleeding in the Intensive Care Unit. (Pubmed Central) -  Jun 1, 2018   
    Patients treated with these drugs for a wide variety of conditions including atrial fibrillation, stroke, coronary artery stent, deep venous thrombosis, and pulmonary embolism will present for emergency surgery and will require management of pharmacologically induced postoperative coagulopathy. We will discuss optimized strategies for reversal of these agents and strategies that are currently under development.
  • ||||||||||  aspirin / Generic mfg.
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  STROKE-VT: DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation (clinicaltrials.gov) -  May 30, 2018   
    P4,  N=4, Terminated, 
    Recruiting --> Active, not recruiting | N=296 --> 112 N=110 --> 4 | Trial completion date: Apr 2019 --> May 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> May 2018
  • ||||||||||  rivaroxaban / Bayer, Generic mfg.
    Clinical, Journal:  Spontaneous HIT syndrome post-knee replacement surgery with delayed recovery of thrombocytopenia: a case report and literature review. (Pubmed Central) -  May 17, 2018   
    Further, including our patient case, 5 of 7 patients with spontaneous HIT syndrome post-orthopedic surgery who received treatment with argatroban developed new and/or progressive lower-limb DVT or recurrent PE despite anticoagulation with this parenteral direct thrombin inhibitor, suggesting that this patient population is at high risk of breakthrough thrombotic events despite treatment with this HIT treatment-approved anticoagulant. Our case also illustrates successful outcome with rivaroxaban for treatment of spontaneous HIT syndrome, consistent with emerging literature supporting safety and efficacy of direct oral anticoagulant therapy for treatment of acute HIT.
  • ||||||||||  rivaroxaban / Generic mfg.
    Trial completion:  X-PRESS: Xarelto Evidence in Real Life of Patients' Preference and Satisfaction Study (clinicaltrials.gov) -  Apr 19, 2018   
    P=N/A,  N=253, Completed, 
    In patients from China, rates of intracranial hemorrhage were numerically lower among those receiving rivaroxaban and consistent with the overall trial. Active, not recruiting --> Completed
  • ||||||||||  rivaroxaban / Generic mfg., enoxaparin sodium / Generic mfg.
    Trial termination, Surgery:  PRONOMOS: PROphylaxis in NOn Major Orthopaedic Surgery (clinicaltrials.gov) -  Apr 18, 2018   
    P3,  N=3603, Terminated, 
    Active, not recruiting --> Completed Recruiting --> Terminated; Remaining outdated treatments and additional costs too high for new manufacturing
  • ||||||||||  rivaroxaban / Generic mfg., apixaban / Generic mfg.
    Trial completion:  COBRRA Pilot: Comparison of Bleeding Risk Between Rivaroxaban and Apixaban (clinicaltrials.gov) -  Apr 17, 2018   
    P4,  N=72, Completed, 
    Recruiting --> Terminated; Remaining outdated treatments and additional costs too high for new manufacturing Active, not recruiting --> Completed
  • ||||||||||  rivaroxaban / Generic mfg., atorvastatin / Generic mfg., warfarin / Generic mfg.
    Trial completion date, Trial primary completion date:  Statin Use in Patients With Acute VTE (clinicaltrials.gov) -  Apr 6, 2018   
    P1/2,  N=80, Recruiting, 
    Trial completion date: Mar 2018 --> Feb 2019 | Trial primary completion date: Mar 2018 --> Dec 2018 Trial completion date: Oct 2018 --> Oct 2019 | Trial primary completion date: Jan 2018 --> Apr 2019
  • ||||||||||  rivaroxaban / Generic mfg.
    Phase classification:  XAPASS: Xarelto [SPAF] Post-marketing Surveillance in Japan (clinicaltrials.gov) -  Apr 3, 2018   
    P,  N=11311, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Phase classification: PN/A --> P Phase classification: P=N/A --> P
  • ||||||||||  rivaroxaban / Generic mfg.
    Phase classification:  Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan (clinicaltrials.gov) -  Mar 30, 2018   
    P,  N=741, Active, not recruiting, 
    Phase classification: P=N/A --> P Phase classification: P=N/A --> P